Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sunshine Biopharma said its anti-cancer compound, Adva-27a, has advanced to the next phase of drug development, namely GMP manufacturing, IND-enabling studies and Phase I clinical trials in humans.
Subscribe to our email newsletter
Sunshine Biopharma president and CEO Steve Slilaty said, "We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing, and recent fund raising efforts."
Adva-27a has proved effective to kill various types of cancer cells and multidrug resistant cancer cells, according to the company.
According to Sunshine, Adva-27a is also effective against Multidrug Resistant Breast Cancer cells (MCF-7/MDR) and Small-Cell Lung Cancer cells (H69AR).
The initial indication for Adva-27a’s phase I human trials will be multidrug resistant breast cancer.
Sunshine has recently taken a new batch of Adva-27a from the Contract Manufacturing Organization and is conducting biological tests to ensure that the newly manufactured batch is identical to the original.
The company has also raised $460,000 for manufacturing and other activities of Adva-27a phase I clinical trial.